All News
Happy Diwali (11.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Iberdomide Efficacy in Cutaneous Lupus
Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
Read Article
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Read Article
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at concept
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN
Dr. John Cush RheumNow ( View Tweet)
Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN)
- 60% PGN w ≤1 g/d proteinuria (more renal recovery)
- 79% w/ 1-3g/d
- 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush RheumNow ( View Tweet)
Blue Collar Arthritis (10.25.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv
Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb
Links:
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Links:
Dr. John Cush RheumNow ( View Tweet)
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush RheumNow ( View Tweet)
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before… https://t.co/31dqOyD3ZR https://t.co/L9LMn2CPYS
Dr. John Cush RheumNow ( View Tweet)
Biomarker substudy of #SLE Rx w/ low dose IL-2 Rx in 342 pts (40% responders). SRI-4 predicted by rash, proteinuria, uRBC, %CD4 T cells, C3 (AUC 0.9330; however renal markers did not correlate with achieving LLDAS. https://t.co/pDgwegbU6t https://t.co/72w4gNAiWt
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/cH4s99Fzka https://t.co/kNcUqahmeS
Dr. John Cush RheumNow ( View Tweet)
Dr. Lindsey Criswell Elected to National Academy of Medicine. Dr. Criswell is the NIAMS Director and is known for her research in SLE, RA, and Sjogrens. Congrats!! https://t.co/3l4VHqnH2m https://t.co/FDcNVGjw4l
Dr. John Cush RheumNow ( View Tweet)
Is EBV relevant? It's certainly been linked to the etiol of SLE, RA, Sjögrens, & MS. Ronbinson et al suggests "EBV infection as a potentiator of autoimmune rheumatic diseases" and if Rx targeting of EBV may work in EBV-associated autoimmune diseases. https://t.co/bi630VvHTx https://t.co/tKYtwePaTu
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush RheumNow ( View Tweet)
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush RheumNow ( View Tweet)
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Links:
Dr. John Cush RheumNow ( View Tweet)
